Sharemaestro Newsreel

Regeneron: Dupixent Sales Reach $6 Billion As Sanofi Repayment Unlocks Profit And Cash Flow Inflection

Regeneron reported strong Q2 2026 growth, with global Dupixent sales reaching approximately $6 billion, exceeding analyst expectations. The company also fully repaid its development balance to Sanofi, removing a significant financial drag and leading to an inflection point in profit and cash flow. This, …

AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb are reportedly in discussions for a merger that could create a pharmaceutical giant valued at approximately $400 billion. The talks have been ongoing for several months and, if successful, would make AstraZeneca the world’s fourth-largest drugmaker by market capitalization. …

AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

AstraZeneca has reportedly held talks with Bristol Myers Squibb regarding a potential merger that could create a pharmaceutical giant valued at nearly $400 billion. The Financial Times reported on Sunday that discussions have occurred in recent months, though a deal could still be delayed …

AstraZeneca, Bristol Myers held merger talks, Financial Times reports (AZN:NYSE)

AstraZeneca (AZN) and Bristol Myers Squibb (BMY) reportedly held preliminary discussions regarding a potential merger. This combination, if it materializes, would result in one of the world's largest pharmaceutical companies. The news was reported by the Financial Times.

ETFs Investing in Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs Stocks

This article lists ETFs that hold Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs stocks, highlighting one specific fund: the CTBC Global High Dividend ETF Securities Investment Trust Fund. It provides financial details such as market value, weight, issuer, management style, expense ratio, …

AstraZeneca, Bristol Myers Squibb Held Talks for Tie-Up, FT Says

AstraZeneca Plc and Bristol Myers Squibb Co. reportedly held discussions about a potential merger to combine the two pharmaceutical companies. The Financial Times, citing familiar sources, stated that these talks occurred in recent months, though the specifics of the deal structure were not detailed …

AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie (ABBV) has successfully diversified its business beyond its previous dependence on Humira, with strong Q2 revenue and earnings growth driven by its Immunology and Neurosciences segments. Analysts maintain a "Moderate Buy" rating, anticipating the stock could reach $300 within 12 months, despite a …

Amarin reports Q2 2026: $42.2M revenue, $14.99M gross profit, $7.7M net loss, positive cash flow

Amarin reported its Q2 2026 results, showing total net revenue of $42.2 million, gross profit of $14.99 million, and a narrowed GAAP net loss of $7.7 million. The company generated positive cash flow and held $314.6 million in cash, driven by rising in-market demand …

Sanofi (ENXTPA:SAN) Ends Amlitelimab Development For Atopic Dermatitis After Pipeline Review

Sanofi has halted the development of amlitelimab for atopic dermatitis after a pipeline review indicated no significant improvement over existing treatments. This decision removes a key immunology asset from its portfolio and raises questions for investors regarding the reallocation of research capital. The market …

Pfizer (PFE) Q2 Earnings: What To Expect

Organon (OGN) Stock Stalls As Margin Compression Keeps Value Debate Alive

Bristol-Myers Squibb Company Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

AbbVie (ABBV) Stock Faces A Pivotal Growth Handoff After Guidance Lift

AbbVie Number of Employees 2026 | Employee Count & Headcount Data

As of March 2026, AbbVie (ABBV) has approximately 57,960 total employees worldwide, a growth of 11.0% since 2023. The company is actively hiring, with 2,862 job postings in 2026, and its workforce is concentrated in the United States, followed by India and Ireland. The …

Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

Eli Lilly and Company announced a definitive agreement to acquire DICE Therapeutics for approximately $2.4 billion. DICE is a biopharmaceutical company focused on developing novel oral therapeutic candidates for chronic immunological diseases using its proprietary DELSCAPE technology platform. This acquisition aims to enhance Lilly's …

Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial

Novo Nordisk's monoclonal antibody ziltivekimab failed to meet its primary endpoint in a Phase III trial (ZEUS) for reducing major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. Although the drug successfully engaged its target and inhibited …

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease

Novartis announced that the FDA has approved Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), expanding its use across all stages of PSMA-positive metastatic prostate cancer. This approval is based on the Phase III PSMAddition trial, which demonstrated that Pluvicto, combined with standard of …

Do Wall Street Analysts Like Gilead Sciences Stock?

Gilead Sciences, Inc. (GILD) has seen its stock outperform the broader market, driven by FDA approval for its breast cancer drug Trodelvy®. Analysts maintain a "Strong Buy" consensus rating for GILD, with an average price target indicating a significant upside. Despite an expected EPS …

Western Wealth Management LLC Increases Stock Position in Amgen Inc. $AMGN

Western Wealth Management LLC significantly increased its stake in Amgen Inc. by 137.5% in the first quarter, now owning 10,207 shares valued at $3.59 million. Other institutional investors have also adjusted their positions in the medical research company. Amgen reported strong Q1 earnings, beating …

Johnson & Johnson embarks on supply chain restructuring

Johnson & Johnson is restructuring its supply chain, primarily within its innovative medicine segment, a project expected to cost up to $750 million and be completed by the end of fiscal year 2029. This initiative involves exiting certain manufacturing locations to streamline operations, with …

Amgen Inc. Revenue Breakdown – FWB:AMG

Amgen Inc. (FWB:AMG) generated 31.29 billion EUR in revenue last year. The Human Therapeutics segment was its top-performing segment, contributing 29.93 billion EUR. The United States was the largest geographical contributor, accounting for 22.49 billion EUR.

Argent Capital Management LLC Trims Stock Position in Amgen Inc. $AMGN

Argent Capital Management LLC reduced its stake in Amgen Inc. by 10.6% in the first quarter, selling 8,963 shares and holding 75,772 shares valued at $26.66 million. Despite this, other institutional investors have increased their holdings, and Amgen announced a quarterly dividend of $2.52 …

AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition

AbbVie has revised its full-year profit forecast downwards as a direct consequence of its recent acquisition of Apogee Therapeutics. This adjustment reflects the financial impact and integration costs associated with the acquisition, signaling a change in the company's expected earnings for the fiscal year.

Alpine Woods Capital Investors LLC Purchases 4,003 Shares of Amgen Inc. $AMGN

Alpine Woods Capital Investors LLC increased its stake in Amgen Inc. by 21.0% in the first quarter, adding 4,003 shares to its portfolio, now owning 23,064 shares valued at $8.115 million. Other institutional investors also adjusted their holdings in Amgen, which constitutes about 1.9% …

Novo Nordisk’s Market Value Sheds $30 Billion—Here’s Why Shares Are Down

Novo Nordisk's market value dropped by over $30 billion after a late-stage experimental heart drug, ziltivekimab, failed to meet its primary goals in a clinical trial. This setback prompted criticism from analysts who viewed it as a missed opportunity for the company to diversify …

MIRA Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:MIRA

This article provides a basic overview of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) and directs users to financial data on TradingView. It indicates that the market is closed with no trades and points to various financial sections like statements, statistics, dividends, and earnings. The article …

AbbVie (ABBV) Stock Could Sit Below Fair Value While Earnings Look Rich

Price to earnings forward of GSK plc – LSE:GSK

This article focuses on the "Price to earnings forward" metric for GSK plc, listed on the London Stock Exchange under the ticker GSK. It appears to be a financial data snippet from a larger platform like TradingView, providing specific financial information without extensive commentary …

Enterprise value to EBIT forward of Scilex Holding Company – NASDAQ:SCLX

This article provides the enterprise value to EBIT forward for Scilex Holding Company (NASDAQ: SCLX). It highlights that the market for SCLX was closed with no trades. The information is presented within the context of financial data provided by TradingView.

Tangible book value per share of MIRA Pharmaceuticals, Inc. – MUN:K6S

This article provides the tangible book value per share for MIRA Pharmaceuticals, Inc. (MUN:K6S) as listed on the Munich Stock Exchange. It indicates that the market was closed at the time of publication and no trades had occurred. The information is presented within a …

Scilex Holding Company Revenue Breakdown – NASDAQ:SCLX

This article provides a revenue breakdown for Scilex Holding Company (NASDAQ: SCLX), highlighting that the United States was the primary contributor to its revenue in the last year, bringing in $30.25 million, a decrease from $56.59 million the year prior. The data is presented …

Vanguard Portfolio Management (OGN) discloses 15.2M-share, 5.77% Organon & Co stake

Vanguard Portfolio Management LLC and affiliated entities have reported a beneficial ownership of 15,161,710 shares in Organon & Co, constituting a 5.77% stake in the company. Vanguard holds sole voting power over 29,592 shares and sole dispositive power over all 15.16 million shares. This …

Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Revenue Breakdown – BCBA:NVSC

Novartis AG (BCBA:NVSC) generated a total revenue of $54.53 billion USD last year. The Oncology segment was its top-performing segment, contributing $17.63 billion USD, an increase from the previous year. The United States was the largest geographical contributor, accounting for $24.44 billion USD of …

Johnson & Johnson Backs In Vivo CAR-T With a Three-Part Deal for Sail Biomedicines

Johnson & Johnson has made a significant investment and collaboration deal with Sail Biomedicines, committing $785 million in initial payments, including a direct equity investment of $465 million. The deal also includes up to $140 million in contingent development milestone payments and an exclusive …

Novartis Ag (0K9E) Q1 2025 Earnings Report - Results, Call & Slides

Novartis Ag (0K9E) released its Q1 2025 earnings report, surpassing analyst expectations with an actual EPS of $2.28 against a consensus of $2.11, and actual revenue of $13.24 billion exceeding the expected $13.08 billion. This represents a significant year-over-year revenue growth of 12.60% and …

Why AbbVie Stock Slumped Today

AbbVie's stock fell by nearly 3% after its second-quarter earnings report, despite strong revenue growth, because its adjusted profitability of $3.65 per share missed analyst estimates of $3.71. Additionally, the company slightly cut its 2026 profitability outlook due to its acquisition of Apogee Therapeutics, …